摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Thiophenecarboxamide, N-(2-((methylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)- | 141284-57-3

中文名称
——
中文别名
——
英文名称
2-Thiophenecarboxamide, N-(2-((methylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-
英文别名
N-[2-(methanesulfonamido)-5-(trifluoromethyl)pyridin-3-yl]thiophene-2-carboxamide
2-Thiophenecarboxamide, N-(2-((methylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-化学式
CAS
141284-57-3
化学式
C12H10F3N3O3S2
mdl
——
分子量
365.4
InChiKey
YVTPHCIICZCPFX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    125
  • 氢给体数:
    2
  • 氢受体数:
    9

文献信息

  • REMEDIES OR PREVENTIVES FOR PULMONARY INSUFFICIENCY CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES
    申请人:ISHIHARA SANGYO KAISHA, LTD.
    公开号:EP1252889A1
    公开(公告)日:2002-10-30
    A therapeutic or preventive agent for pulmonary insufficiency, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: wherein X is a -CW1R1 group, a -COCOR2 group, a -CW1NHCOR2 group, a -C(=W1)W2R3 group or a -CW1N(R4)R5 group; Y is an alkyl group, a -CW3R6 group, a -COCOR7 group, a -NHCOR7 group, a -C(=W3)W4R8 group, a -(NH)mSO2R9 group, a -(NH)mSO2OR10 group or a -(NH)mSO2N(R11)R12 group; each of R1, R6 and R9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R2 and R7 is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R3, R8 and R10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R4, R5, R11 and R12 is an alkyl group; each of W1, W2, W3 and W4 is an oxygen atom or a sulfur atom; and m is 0 or 1, is provided.
    一种治疗或预防肺功能不全的药物,其活性成分含有由式(I)或其盐代表的二氨基三氟甲基吡啶衍生物: 其中 X 是-CW1R1 基团、-COCOR2 基团、-CW1NHCOR2 基团、-C(=W1)W2R3 基团或-CW1N(R4)R5 基团;Y 是烷基、-CW3R6 基团、-COCOR7 基团、-NHCOR7 基团、-C(=W3)W4R8 基团、-(NH)mSO2R9 基团、-(NH)mSO2OR10 基团或-(NH)mSO2N(R11)R12 基团;R1、R6 和 R9 中的每一个是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团;R2和R7各自为烷基、烷氧基、苯基或苯氧基; R3、R8和R10各自为烷基、烯基、炔基、环烷基、苯基或苄基; R4、R5、R11和R12各自为烷基; W1、W2、W3和W4各自为氧原子或硫原子;以及 m为0或1。
  • REMEDIES OR PREVENTIVES FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES
    申请人:ISHIHARA SANGYO KAISHA, LTD.
    公开号:EP1252890A1
    公开(公告)日:2002-10-30
    A digestive system disease therapeutic or preventive agent containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: wherein X is a -CW1R1 group, a -COCOR2 group, a -CW1NHCOR2 group, a -C(=W1)W2R3 group or a -CW1N(R4)R5 group; Y is an alkyl group, a -CW3R6 group, a -COCOR7 group, a -NHCOR7 group, a -C(=W3)W4R8 group, a -(NH)mSO2R9 group, a -(NH)mSO2OR10 group or a -(NH)mSO2N(R11)R12 group; each of R1, R6 and R9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R2 and R7 is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R3, R8 and R10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R4, R5, R11 and R12 is an alkyl group; each of W1, W2, W3 and W4 is an oxygen atom or a sulfur atom; and m is 0 or 1.
    一种消化系统疾病治疗剂或预防剂,其活性成分含有由式(I)或其盐代表的二氨基三氟甲基吡啶衍生物: 其中 X 是-CW1R1 基团、-COCOR2 基团、-CW1NHCOR2 基团、-C(=W1)W2R3 基团或-CW1N(R4)R5 基团;Y 是烷基、-CW3R6 基团、-COCOR7 基团、-NHCOR7 基团、-C(=W3)W4R8 基团、-(NH)mSO2R9 基团、-(NH)mSO2OR10 基团或-(NH)mSO2N(R11)R12 基团;R1、R6 和 R9 中的每一个是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团;R2和R7各自为烷基、烷氧基、苯基或苯氧基; R3、R8和R10各自为烷基、烯基、炔基、环烷基、苯基或苄基; R4、R5、R11和R12各自为烷基; W1、W2、W3和W4各自为氧原子或硫原子;以及 m为0或1。
  • REMEDIES OR PREVENTIVES FOR LIVER DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES
    申请人:ISHIHARA SANGYO KAISHA, LTD.
    公开号:EP1252891A1
    公开(公告)日:2002-10-30
    A therapeutic or preventive agent for liver diseases, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: wherein X is a -CW1R1 group, a -COCOR2 group, a -CW1NHCOR2 group, a -C(=W1)W2R3 group or a -CW1N(R4)R5 group; Y is an alkyl group, a -CW3R6 group, a -COCOR7 group, a -NHCOR7 group, a -C(=W3)W4R8 group, a -(NH)mSO2R9 group, a -(NH)mSO2OR10 group or a -(NH)mSO2N(R11)R12 group; each of R1, R6 and R9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R2 and R7 is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R3, R8 and R10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R4, R5, R11 and R12 is an alkyl group; each of W1, W2, W3 and W4 is an oxygen atom or a sulfur atom; . and m is 0 or 1, is provided.
    一种治疗或预防肝病的药物,其有效成分含有由式(I)或其盐代表的二氨基三氟甲基吡啶衍生物: 其中 X 是-CW1R1 基团、-COCOR2 基团、-CW1NHCOR2 基团、-C(=W1)W2R3 基团或-CW1N(R4)R5 基团;Y 是烷基、-CW3R6 基团、-COCOR7 基团、-NHCOR7 基团、-C(=W3)W4R8 基团、-(NH)mSO2R9 基团、-(NH)mSO2OR10 基团或-(NH)mSO2N(R11)R12 基团;R1、R6 和 R9 中的每一个是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团;R2和R7各自为烷基、烷氧基、苯基或苯氧基; R3、R8和R10各自为烷基、烯基、炔基、环烷基、苯基或苄基; R4、R5、R11和R12各自为烷基; W1、W2、W3和W4各自为氧原子或硫原子; .和 m 为 0 或 1。
  • Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
    申请人:——
    公开号:US20030018054A1
    公开(公告)日:2003-01-23
    A therapeutic or preventive agent for liver diseases, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: 1 wherein X is a —CW 1 R 1 group, a —COCOR 2 group, a —CW 1 NHCOR 2 group, a —C(═W 1 )W 2 R 3 group or a —CW 1 N(R 4 )R 5 group; Y is an alkyl group, a —CW 3 R 6 group, a —COCOR 7 group, a —NHCOR 7 group, a —C(═W 3 )W 4 R 8 group, a —(NH) m SO 2 R 9 group, a —(NH) m SO 2 OR 10 group or a —(NH) m SO 2 N(R 11 )R 12 group; each of R 1 , R 6 and R 9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R 2 and R 7 is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R 3 , R 8 and R 10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R 4 , R 5 , R 11 and R 12 is an alkyl group; each of W 1 , W 2 , W 3 and W 4 is an oxygen atom or a sulfur atom; and m is 0 or 1, is provided.
    一种治疗或预防肝脏疾病的药物,其活性成分为式 (I) 所代表的二氨基三氟甲基吡啶衍生物或其盐: 1 其中 X 是 -CW 1 R 1 基团 2 基团、一个 -CW 1 NHCOR 2 基团,一个 -C(═W 1 )W 2 R 3 基团或-CW 1 N(R 4 )R 5 基团;Y 是烷基、-CW 3 R 6 基团、一个 -COCOR 7 基团、一个 -NHCOR 7 基团、一个 -C(═W 3 )W 4 R 8 基团,一个-(NH) m SO 2 R 9 基团,一个-(NH) m SO 2 或 10 基团或-(NH) m SO 2 N(R 11 )R 12 基团;每个 R 1 , R 6 和 R 9 是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团;R 2 和 R 7 是烷基、烷氧基、苯基或苯氧基;R 3 , R 8 和 R 10 是烷基、烯基、炔基、环烷基、苯基或苄基;每个 R 4 , R 5 , R 11 和 R 12 是烷基 1 , W 2 , W 3 和 W 4 为氧原子或硫原子;m 为 0 或 1。
  • Remedies or preventives for digestive diseases containing diaminotrifluoromethypyridine derivatives
    申请人:——
    公开号:US20030027843A1
    公开(公告)日:2003-02-06
    A digestive system disease therapeutic or preventive agent containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: 1 wherein X is a —CW 1 R 1 group, a —COCOR 2 group, a —CW 1 NHCOR 2 group, a —C(═W 1 )W 2 R 3 group or a —CW 1 N(R 4 )R 5 group; Y is an alkyl group, a —CW 3 R 6 group, a —COCOR 7 group, a —NHCOR 7 group, a —C(═W 3 )W 4 R 8 group, a —(NH) m SO 2 R 9 group, a —(NH) m SO 2 OR 10 group or a —(NH) m SO 2 N(R 11 )R 12 group; each of R 1 , R 6 and R 9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R 2 and R 7 is an-alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R 3 , R 8 and R 10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R 4 , R 5 , R 11 and R 12 is an alkyl group; each of W 1 , W 2 , W 3 and W 4 is an oxygen atom or a sulfur atom; and m is 0 or 1.
    一种消化系统疾病治疗剂或预防剂,其活性成分含有式 (I) 所代表的二氨基三氟甲基吡啶衍生物或其盐: 1 其中 X 是 -CW 1 R 1 基团 2 基团、一个 -CW 1 NHCOR 2 基团,一个 -C(═W 1 )W 2 R 3 基团或-CW 1 N(R 4 )R 5 基团;Y 是烷基、-CW 3 R 6 基团、一个 -COCOR 7 基团、一个 -NHCOR 7 基团、一个-C(═W 3 )W 4 R 8 基团,一个-(NH) m SO 2 R 9 基团,一个-(NH) m SO 2 或 10 基团或-(NH) m SO 2 N(R 11 )R 12 基团;每个 R 1 , R 6 和 R 9 是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团;R 2 和 R 7 是烷基、烷氧基、苯基或苯氧基;R 3 , R 8 和 R 10 是烷基、烯基、炔基、环烷基、苯基或苄基;每个 R 4 , R 5 , R 11 和 R 12 是烷基 1 , W 2 , W 3 和 W 4 是氧原子或硫原子;m 是 0 或 1.
查看更多

同类化合物

阿罗洛尔 阿替卡因 阿克兰酯 锡烷,(5-己基-2-噻吩基)三甲基- 邻氨基噻吩(2盐酸) 辛基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 辛基4,6-二溴噻吩并[3,4-b]噻吩-2-羧酸酯 辛基2-甲基异巴豆酸酯 血管紧张素IIAT2受体激动剂 葡聚糖凝胶LH-20 苯螨噻 苯并[c]噻吩-1-羧酸,5-溴-4,5,6,7-四氢-3-(甲硫基)-4-羰基-,乙基酯 苯并[b]噻吩-2-胺 苯并[b]噻吩-2-胺 苯基-[5-(4,4,5,5-四甲基-[1,3,2]二氧杂硼烷-2-基)-噻吩-2-基亚甲基]-胺 苯基-(5-氯噻吩-2-基)甲醇 苯乙酸,-α--[(1-羰基-2-丙烯-1-基)氨基]- 苯乙酰胺,3,5-二氨基-a-羟基-2,4,6-三碘- 苯乙脒,2,6-二氯-a-羟基- 腈氨噻唑 聚(3-丁基噻吩-2,5-二基),REGIOREGULAR 硝呋肼 硅烷,(3-己基-2,5-噻吩二基)二[三甲基- 硅噻菌胺 盐酸阿罗洛尔 盐酸阿罗洛尔 盐酸多佐胺 甲酮,[5-(1-环己烯-1-基)-4-(2-噻嗯基)-1H-吡咯-3-基]-2-噻嗯基- 甲基5-甲酰基-4-甲基-2-噻吩羧酸酯 甲基5-乙氧基-3-羟基-2-噻吩羧酸酯 甲基5-乙基-3-肼基-2-噻吩羧酸酯 甲基5-(氯甲酰基)-2-噻吩羧酸酯 甲基5-(氯乙酰基)-2-噻吩羧酸酯 甲基5-(氨基甲基)噻吩-2-羧酸酯 甲基5-(4-甲氧基苯基)-2-噻吩羧酸酯 甲基5-(4-甲基苯基)-2-噻吩羧酸酯 甲基5-(1,3-二氧戊环-2-基)-2-噻吩羧酸酯 甲基4-硝基-2-噻吩羧酸酯 甲基4-氰基-5-(4,6-二氨基吡啶-2-基)偶氮-3-甲基噻吩-2-羧酸酯 甲基4-氨基-5-(甲硫基)-2-噻吩羧酸酯 甲基4-{[(2E)-2-(4-氰基苯亚甲基)肼基]磺酰}噻吩-3-羧酸酯 甲基4-(氯甲酰基)-3-噻吩羧酸酯 甲基4-(氨基磺酰基氨基)-3-噻吩羧酸酯 甲基3-甲酰氨基-4-甲基-2-噻吩羧酸酯 甲基3-氨基-5-异丙基-2-噻吩羧酸酯 甲基3-氨基-5-(4-溴苯基)-2-噻吩羧酸酯 甲基3-氨基-4-苯基-5-(三氟甲基)-2-噻吩羧酸酯 甲基3-氨基-4-氰基-5-甲基-2-噻吩羧酸酯 甲基3-氨基-4-丙基-2-噻吩羧酸酯 甲基3-[[(4-甲氧基苯基)亚甲基氨基]氨基磺酰基]噻吩-2-羧酸酯